Reports Q3 revenue $16.4M, consensus $19.16M. “We are pleased to share the significant progress made during the third quarter of 2023, highlighted by the advancement of our robust pipeline of targeted oncology programs and continued launch execution of KRAZATI,” said CEO Charles Baum. “As we shared last month, we believe our pending acquisition by Bristol Myers Squibb will support the realization of the full potential of our therapies and enable the promise of a life beyond cancer. We look forward to continuing our work to improve the lives of people with cancer through Mirati discovered and developed therapeutics.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
- MRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mirati Therapeutics receives MHRA approval for KRAZATI
- Kura Oncology, Mirati Therapeutics enter clinical collab, supply agreement
- Short Report: ChargePoint, Luminar short positions at highest levels in weeks
